Synthesis and Characterization of Impurities in Rasagiline: A Novel MAO-B Inhibitor in Parkinson’s Disease Therapy
摘要:
雷沙吉兰 (1) 被 FDA 批准作为治疗帕金森病的辅助疗法和单一疗法。在雷沙吉兰的工艺开发过程中,与最终 API 一起观察到的工艺相关杂质很少。这些杂质被鉴定为茚满醇(2)、茚满胺(3)、烯丙基(4)、酮(7)、其他异构体(6)和氯烯丙基(5,5a)杂质。目前的工作描述了所有这些杂质的合成,并通过 1H NMR 和质谱分析进行表征。
A process for the preparation of (R)-1-aminoindanes
申请人:Chemo Ibérica, S.A.
公开号:EP2181980A1
公开(公告)日:2010-05-05
The present invention relates to a process for the preparation of the chiral compound of formula (V), wherein R1 is a C1-C6 alkyl group optionally substituted with halogens, an aryl optionally substituted, or a trialkyl silyl group, for use as an intermediate in the preparation of (R)-1-amino indanes, helpful in the pharmaceutical field. The compound of formula (V) is a key intermediate to the preparation of (R)-1-aminoindanes, particularly Rasagiline. The invention also relates to novel compounds, which are especially useful as intermediates for the preparation of (R)-1-aminoindanes.
[EN] A PROCESS FOR THE PREPARATION OF (R)-I -AMINOINDANES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE (R)-1-AMINOINDANES
申请人:CHEMO IBERICA SA
公开号:WO2010049379A1
公开(公告)日:2010-05-06
The present invention relates to a process for the preparation of the chiral compound of formula (V), wherein R1 is a C1-C6 alkyl group optionally substituted with halogens, an aryl optionally substituted, or a trialkyl silyl group, for use as an intermediate in the preparation of (R)-1-aminoindanes, helpful in the pharmaceutical field. The compound of formula (V) is a key intermediate to the preparation of (R)-1- aminoindanes, particularly Rasagiline. The invention also relates to novel compounds, which are especially useful as intermediates for the preparation of (R)-1- aminoindanes.